Prevalence of nonalcoholic fatty liver disease in the United States: The third national health and nutrition examination survey, 1988-1994

American Journal of Epidemiology

Volumn 178, Issue 1, 2013, Pages 38-45

  Lazo, Mariana ^a   Hernaez, Ruben ^a,b   Eberhardt, Mark S ^c   Bonekamp, Susanne ^a   Kamel, Ihab ^a   Guallar, Eliseo ^a   Koteish, Ayman ^a   Brancati, Frederick L ^a   Clark, Jeanne M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c NATIONAL CENTER FOR HEALTH STATISTICS   (United States)

Author keywords

ethnic variation; nonalcoholic fatty liver disease; population surveys; prevalence

Indexed keywords

BODY MASS; DIABETES; DISEASE PREVALENCE; ENZYME ACTIVITY; OBESITY; POPULATION STRUCTURE; PUBLIC HEALTH; SURVEY;

ADULT; AGED; ALCOHOL CONSUMPTION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ECHOGRAPHY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREVALENCE; REVIEW; UNITED STATES;

ETHNIC VARIATION; NONALCOHOLIC FATTY LIVER DISEASE; POPULATION SURVEYS; PREVALENCE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; FATTY LIVER; FEMALE; HUMANS; LIVER; MALE; MEXICAN AMERICANS; MIDDLE AGED; NUTRITION SURVEYS; PREVALENCE; SEX FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES; YOUNG ADULT;

UNITED STATES;

EID: 84880245463     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws448     Document Type: Review

References (44)

1. US Center for Disease Control and Prevention. Vital statistics of the United States. Mortality, 1988-2006. Hyattsville, MD: National Center for Health Statistics; 1988. (http://www.cdc. gov/nchs/data-access/vitalstatsonline.htm). (Accessed October 1, 2010
2. Hoyert DL, Xu JQ. Deaths: Preliminary data for 2011. In: National Vital Statistics Reports. Vol. 61, no. 6. Hyattsville, MD: National Center for Health Statistics; 2012
3. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: Summary of an AASLD single topic conference. Hepatology. 2003;37(5):1202-1219
4. Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53(2):372-384
5. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705-1725
6. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960-967
7. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol. 2006; 101(1):76-82
8. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: Results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci. 2005;329(3):111-116
9. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology. 2003;124(1): 71-79
10. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology. 2004;40(6):1387-1395
11. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: A global perspective. Semin Liver Dis. 2008; 28(4):339-350
12. Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: A clinical histopathological study. Am J Gastroenterol. 2003;98(9):2042-2047
13. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-1419
14. Wong VW, Wong GL, Choi PC, et al. Disease progression of non-Alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. Gut. 2010;59(7):969-974
15. Argo CK, Caldwell SH. Epidemiology and natural history of non-Alcoholic steatohepatitis. Clin Liver Dis. 2009;13(4): 511-531
16. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology. 1999;29(3):664-669
17. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51(6): 1972-1978
18. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134-140
19. National Center for Health Statistics. Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988-1994. Hyattsville, MD: National Center for Health Statistics;1994. (Vital and health statistics, series 1: Programs and collection procedures, no. 32) (DHHS publication no. (PHS) 94-1308) (GPO no. 017-022-01260-0
20. Third National Health and Nutrition Examination Survey: Gallbladder Ultrasonography Procedure Manual. Rockville, MD:Westat, Inc; 1988
21. National Center for Health Statistics. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Hyattsville, MD: National Center for Health Statistics; 1996
22. Chen J,Wildman RP, Hamm LL, et al. Association between inflammation and insulin resistance in U.S. nondiabetic adults: Results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2004;27(12):2960-2965
23. National Center for Health Statistics. Third National Health and Nutrition Examination Survey: Hepatic Steatosis Assessment Procedure Manual. Hyattsville, MD: National Center for Health Statistics; 2010
24. Becker U, Deis A, Sorensen TI, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: A prospective population study. Hepatology. 1996;23(5):1025-1029
25. Bellentani S, Saccoccio G, Costa G, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut. 1997;41(6):845-850
26. Coates RA, Halliday ML, Rankin JG, et al. Risk of fatty infiltration or cirrhosis of the liver in relation to ethanol consumption: A case-control study. Clin Invest Med. 1986; 9(1):26-32
27. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346(16):1221-1231
28. National Center for Health Statistics. Analytical and Reporting Guidelines: The Third National Health and Nutrition Examination Survey, NHANES III (1988-1994). Hyattsville, MD: National Center for Health Statistics; 1996
29. Petersen MR, Deddens JA. A comparison of two methods for estimating prevalence ratios. BMC Med Res Methodol. 2008;8:9
30. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272(3):205-211
31. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295(13):1549-1555
32. Vital signs: State-specific obesity prevalence among adults- United States, 2009. MMWR Morb Mortal Wkly Rep. 2010; 59(early release):1-5
33. Kim WR, Brown RS Jr, Terrault NA, et al. Burden of liver disease in the United States: Summary of a workshop. Hepatology. 2002;36(1):227-242
34. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141(4):1249-1253
35. Sanyal A, Poklepovic A, Moyneur E, et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin. 2010;26(9):2183-2191
36. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37(6):1286-1292
37. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3): 913-924
38. Lazo M, Selvin E, Clark JM. Brief communication: Clinical implications of short-Term variability in liver function test results. Ann Intern Med. 2008;148(5):348-352
39. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-Aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology. 2011;140(1):124-131
40. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-Analysis. Hepatology. 2011;54(3):1082-1090
41. Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33(10):2156-2163
42. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1): 121-129
43. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675-1685
44. Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial 26. Gastroenterology. 2008;135(1):100-110 Kidney Diseases